Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival

被引:63
作者
Smith, K [1 ]
Fox, SB
Whitehouse, R
Taylor, M
Greenall, M
Clarke, J
Harris, AL
机构
[1] John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Lab, Oxford OX3 9DU, England
[2] John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England
[3] John Radcliffe Hosp, Dept Surg, Oxford OX3 9DU, England
关键词
breast cancer; fibroblast growth factor; microvasculature;
D O I
10.1023/A:1008303614441
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Angiogenesis, the process whereby endothelial cells divide and migrate to form new blood capillaries, has been assessed in tumours by measuring microvessel density. High microvessel density is a significant adverse prognostic factor in breast cancer. The angiogenic factor, basic fibroblast growth factor (bFGF), has been associated with tumourigenesis and metastasis in several human cancers. There are few quantitative studies of bFGF expression in normal tissues compared to cancer. Patients and methods: We have measured bFGF levels in 149 human primary breast carcinomas and assessed the findings in relation to microvessel density, oestrogen receptor (ER) and epidermal growth factor receptor (EGFR). Basic FGF levels were measured by ELISA. Western blotting and immunohistochemistry were carreid out to confirm the presence of bFGF. Results: Levels of bFGF were more than 10-fold higher in tumour cytosols compared to reduction mammoplasty tissue and 3-fold compared to non neoplastic cytosols from the same breast as the tumour (P < 0.0001). Immunohistochemistry showed bFGF protein was localised exclusively in the stroma whereas no bFGF staining was observed in the epithelial cells. High bFGF levels were significantly related to high ER (P = 0.01). Similarly, high bFGF levels were significantly related to low grade (P = 0.046) and to small tumour size (P = 0.04). No significant relationship was observed between bFGF and microvessel count, EGFR or age. In univariate analysis and in a Cox proportional hazard model bFGF did not reach significance for overall or relapse free survival. Conclusions: Our results show that although bFGF is elevated in breast carcinomas compared to normal breast tissue it is not related to microvessel density and it is not an independent predictor of survival in breast cancer patients. Basic FGF may be one of multiple factors that synergise with other growth factors such as VEGF to enhance angiogenesis.
引用
收藏
页码:707 / 713
页数:7
相关论文
共 47 条
[1]  
ANNANDAPPA SY, 1994, BRIT J CANCER, V69, P772
[2]  
Arnaud E, 1999, MOL CELL BIOL, V19, P505
[4]   BASIC FIBROBLAST GROWTH-FACTOR BINDS TO SUBENDOTHELIAL EXTRACELLULAR-MATRIX AND IS RELEASED BY HEPARITINASE AND HEPARIN-LIKE MOLECULES [J].
BASHKIN, P ;
DOCTROW, S ;
KLAGSBRUN, M ;
SVAHN, CM ;
FOLKMAN, J ;
VLODAVSKY, I .
BIOCHEMISTRY, 1989, 28 (04) :1737-1743
[5]  
Blanckaert VD, 1998, CLIN CANCER RES, V4, P2939
[6]   MICROVESSEL QUANTITATION AND PROGNOSIS IN INVASIVE BREAST-CARCINOMA [J].
BOSARI, S ;
LEE, AKC ;
DELELLIS, RA ;
WILEY, BD ;
HEATLEY, GJ ;
SILVERMAN, ML .
HUMAN PATHOLOGY, 1992, 23 (07) :755-761
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   Low levels of basic fibroblast growth factor (bFGF) are associated with a Poor Prognosis in human breast carcinoma [J].
Colomer, R ;
Aparicio, J ;
Montero, S ;
Guzman, C ;
Larrodera, L ;
CortesFunes, H .
BRITISH JOURNAL OF CANCER, 1997, 76 (09) :1215-1220
[9]   The location of acidic fibroblast growth factor in the breast is dependent on the activity of proteases present in breast cancer tissue [J].
Coope, RC ;
Browne, PJ ;
Yiangou, C ;
Bansal, GS ;
Walters, J ;
Groome, N ;
Shousha, S ;
Johnston, CL ;
Coombes, RC ;
Gomm, JJ .
BRITISH JOURNAL OF CANCER, 1997, 75 (11) :1621-1630
[10]   TUMORIGENESIS BY MOUSE MAMMARY-TUMOR VIRUS - PROVIRAL ACTIVATION OF A CELLULAR GENE IN THE COMMON INTEGRATION REGION INT-2 [J].
DICKSON, C ;
SMITH, R ;
BROOKES, S ;
PETERS, G .
CELL, 1984, 37 (02) :529-536